HK2 and ovarian cancer: Here, we assessed whether the pharmacological inhibitor 3-bromopyruvic acid (3-BP)—shown to dissociate HKII from mitochondria treated together with CDDP [19]—sensitizes chemoresistant ovarian cancer cells.